Lexicon Pharmaceuticals, Inc. (LXRX)

NCM – Real Time Price. Currency in USD

2.38

-0.05 (-2.06%)

Market open: Aug 12, 2026, 10:20 AM EDT

2.41

-0.02 (-0.82%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

06.08.2026

Lexicon Pharmaceuticals Q2 Earnings Call Highlights

Lexicon Pharmaceuticals NASDAQ: LXRX reported a wider second-quarter loss as revenue declined sharply from the prior-year period, while the company highlighted completed enrollment in its Phase III SONATA-HCM trial and outlined plans to resubmit a new drug application for ZYNQUISTA in type 1 diabetes during the fourth quarter.

06.08.2026

Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call Transcript

06.08.2026

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates

Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.06 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.01 per share a year ago.

06.08.2026

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

Enrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027 NDA resubmission activities for ZYNQUISTA ® in type 1 diabetes nearing completion Phase 1 clinical development of LX9851 ongoing by Novo Nordisk Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2026, and provided an update on key corporate milestones and accomplishments. “Lexicon continued to make strong progress during the second quarter, with the refinement of our strategy and sharpening of our focus beginning to bear fruit across our business,” said Mike Exton, Ph.D.

Videos

No Data

There is no data to display

Lexicon Pharmaceuticals, Inc. (LXRX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Lexicon Pharmaceuticals, Inc. (LXRX)

Lexicon Pharmaceuticals Q2 Earnings Call Highlights

Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call Transcript

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

Videos

No Data

Lexicon Pharmaceuticals Q2 Earnings Call Highlights

Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call Transcript

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

Videos

No Data

Press releases

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

Search stocks

Lexicon Pharmaceuticals, Inc. (LXRX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Lexicon Pharmaceuticals, Inc. (LXRX)

Lexicon Pharmaceuticals Q2 Earnings Call Highlights

Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call Transcript

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

Videos

No Data

Lexicon Pharmaceuticals Q2 Earnings Call Highlights

Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call Transcript

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

Videos

No Data

Press releases

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates